Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
With the prolongation of the overall survival time of patients with malignant tumors, the
influence of oxaliplatin on the quality of life of patients with malignant tumors has
gradually become prominent. Studies have shown that acetyl-L-carnitine can improve the energy
metabolism of neurotransmitters and inhibit the release of glutamine in the intersynaptic
space to reduce pain. Large-scale clinical studies have approved it as a treatment for
diabetic peripheral neuropathy. Some small model studies have also found that
acetyl-L-carnitine has a definite therapeutic effect on peripheral neurological lesions
induced by chemotherapy. The aim of this study is to investigate the safety and efficacy of
acetyl-L-carnitine in the prevention of oxaliplatin-induced peripheral neuropathy. The study
was divided into an experimental group and a control group. The experimental group was given
acetyl-L-carnitine orally, and the researchers regularly evaluated the symptoms and
electrophysiological indicators related to peripheral neuropathy. If there is a severe
adverse reaction related to acetyl-L-carnitine, the drug should be discontinued and the
symptomatic treatment should be given. After the completion of the study, the statistical
calculation and analysis will be used to estimate whether the preventive and therapeutic
effect of acetyl-L-carnitine on oxaliplatin-induced peripheral neuropathy was statistically
significant.